F Balkwill

Summary

Affiliation: Imperial Cancer Research Fund
Country: UK

Publications

  1. ncbi Cancer and the chemokine network
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Cancer 4:540-50. 2004
  2. ncbi Interferons and cytokines on a grand scale
    F Balkwill
    Imperial Cancer Research Fund, Lincolns Inn Fields, London, U K
    Cytokine Growth Factor Rev 8:91-5. 1997
  3. ncbi Inflammation and cancer: back to Virchow?
    F Balkwill
    ICRF Translational Oncology Laboratory, St Bartholomew s and Royal London School of Medicine and Dentistry, UK
    Lancet 357:539-45. 2001
  4. ncbi Tumor necrosis factor or tumor promoting factor?
    Fran Balkwill
    ICRF Translational Oncology Laboratory, Barts and The London, Queen Mary s School of Medicine and Dentistry, Science Building, Charterhouse Square, London EC1M 6BQ, UK
    Cytokine Growth Factor Rev 13:135-41. 2002
  5. ncbi Cancer and inflammation: implications for pharmacology and therapeutics
    F Balkwill
    Centre for Cancer and Inflammation, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Clin Pharmacol Ther 87:401-6. 2010
  6. ncbi Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF
    S T Malik
    Biological Therapies Laboratory, Imperial Cancer Research Fund, Lincoln s Inn Fields, London
    Br J Cancer 63:399-403. 1991
  7. ncbi Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model
    S Dias
    Biological Therapies Laboratory, Imperial Cancer Research Fund, London, UK
    Int J Cancer 75:151-7. 1998
  8. ncbi The role of cytokines in the epithelial cancer microenvironment
    Julia Wilson
    ICRF Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, London EC1M 6BQ, UK
    Semin Cancer Biol 12:113-20. 2002
  9. ncbi Fran Balkwill
    Fran Balkwill
    J Cell Sci 118:1339-40. 2005
  10. ncbi Cancer: an inflammatory link
    Fran Balkwill
    Nature 431:405-6. 2004

Collaborators

  • A Mantovani
  • S Dias
  • L M Coussens
  • Hagen Kulbe
  • Peter Szlosarek
  • Lucy Wall
  • Julia Wilson
  • Julia L Wilson
  • Neil R Levinson
  • Frances Burke
  • Caroline Barton
  • John Smyth
  • S T Malik
  • D Martin
  • I Hart

Detail Information

Publications15

  1. ncbi Cancer and the chemokine network
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Cancer 4:540-50. 2004
  2. ncbi Interferons and cytokines on a grand scale
    F Balkwill
    Imperial Cancer Research Fund, Lincolns Inn Fields, London, U K
    Cytokine Growth Factor Rev 8:91-5. 1997
    ....
  3. ncbi Inflammation and cancer: back to Virchow?
    F Balkwill
    ICRF Translational Oncology Laboratory, St Bartholomew s and Royal London School of Medicine and Dentistry, UK
    Lancet 357:539-45. 2001
    ..In this article we have provided a rationale for the use of cytokine and chemokine blockade, and further investigation of non-steroidal anti-inflammatory drugs, in the chemoprevention and treatment of malignant diseases...
  4. ncbi Tumor necrosis factor or tumor promoting factor?
    Fran Balkwill
    ICRF Translational Oncology Laboratory, Barts and The London, Queen Mary s School of Medicine and Dentistry, Science Building, Charterhouse Square, London EC1M 6BQ, UK
    Cytokine Growth Factor Rev 13:135-41. 2002
  5. ncbi Cancer and inflammation: implications for pharmacology and therapeutics
    F Balkwill
    Centre for Cancer and Inflammation, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Clin Pharmacol Ther 87:401-6. 2010
    ..Smoldering, nonresolving inflammation is a component of the tumor microenvironment. The linkage between inflammation and cancer, first perceived in the nineteenth century, is now part of an accepted paradigm of carcinogenesis...
  6. ncbi Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF
    S T Malik
    Biological Therapies Laboratory, Imperial Cancer Research Fund, Lincoln s Inn Fields, London
    Br J Cancer 63:399-403. 1991
    ....
  7. ncbi Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model
    S Dias
    Biological Therapies Laboratory, Imperial Cancer Research Fund, London, UK
    Int J Cancer 75:151-7. 1998
    ..Comparison of IL-12 and IFN-gamma suggests that sustained induction of IP-10 and activation of a resulting cellular infiltrate may be key changes in regressing tumours...
  8. ncbi The role of cytokines in the epithelial cancer microenvironment
    Julia Wilson
    ICRF Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, London EC1M 6BQ, UK
    Semin Cancer Biol 12:113-20. 2002
    ....
  9. ncbi Fran Balkwill
    Fran Balkwill
    J Cell Sci 118:1339-40. 2005
  10. ncbi Cancer: an inflammatory link
    Fran Balkwill
    Nature 431:405-6. 2004
  11. ncbi The chemokine network in cancer--much more than directing cell movement
    Hagen Kulbe
    Cancer Research UK, Translational Oncology Laboratory, Queen Mary's School of Medicine and Dentistry, London EC1M 6BQ, UK
    Int J Dev Biol 48:489-96. 2004
    ....
  12. ncbi The significance of cancer cell expression of the chemokine receptor CXCR4
    Fran Balkwill
    Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, London EC1M 6BQ, UK
    Semin Cancer Biol 14:171-9. 2004
    ..However CXCR4 plays major roles in embryogenesis, homeostasis and inflammation. This raises questions concerning the specificity of CXCR4 antagonists in the treatment of cancer...
  13. ncbi The inflammatory cytokine network of epithelial cancer: therapeutic implications
    Peter Szlosarek
    Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, John Vane Science Centre, London EC1M 6BQ, UK
    Novartis Found Symp 256:227-37; discussion 237-40, 259-69. 2004
    ..Agents that antagonize TNFalpha or chemokines are currently being assessed in preclinical animal cancer models and in phase I clinical trials...
  14. ncbi Chemokine biology in cancer
    Fran Balkwill
    Cancer Research UK, Translational Oncology Laboratory Barts, The London Charterhouse Square, Queen Mary s Medical School, London EC1M 6BQ, UK
    Semin Immunol 15:49-55. 2003
    ..Detailed study of chemokine and chemokine receptor antagonists in experimental cancer models is warranted. Manipulation of the tumor chemokine network could have therapeutic potential in malignant disease...
  15. ncbi IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro
    Lucy Wall
    Cancer Research UK, University Department of Oncology, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
    Clin Cancer Res 9:2487-96. 2003
    ..CONCLUSIONS: IFN-gamma induces apoptosis in vitro and in vivo in human epithelial ovarian cancer...